NASDAQ:AVTX Avalo Therapeutics (AVTX) Stock Forecast, Price & News $0.14 0.00 (-0.29%) (As of 12:58 PM ET) Add Compare Share Share Today's Range$0.13▼$0.1450-Day Range$0.08▼$0.2352-Week Range$0.08▼$7.00Volume43.54 million shsAverage Volume18.61 million shsMarket Capitalization$2.83 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Avalo Therapeutics MarketRank™ ForecastAnalyst RatingReduce1.67 Rating ScoreUpside/Downside7,379.4% Upside$10.00 Price TargetShort InterestBearish15.78% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($4.12) to ($4.62) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.62 out of 5 stars 2.8 Analyst's Opinion Consensus RatingAvalo Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Avalo Therapeutics has a forecasted upside of 7,379.4% from its current price of $0.13.Amount of Analyst CoverageAvalo Therapeutics has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted15.78% of the float of Avalo Therapeutics has been sold short.Short Interest Ratio / Days to CoverAvalo Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Avalo Therapeutics has recently increased by 220.13%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAvalo Therapeutics does not currently pay a dividend.Dividend GrowthAvalo Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVTX. Previous Next 2.4 News and Social Media Coverage News SentimentAvalo Therapeutics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Avalo Therapeutics this week, compared to 1 article on an average week.Search Interest37 people have searched for AVTX on MarketBeat in the last 30 days. This is an increase of 429% compared to the previous 30 days.MarketBeat Follows20 people have added Avalo Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avalo Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders45.40% of the stock of Avalo Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 19.28% of the stock of Avalo Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Avalo Therapeutics are expected to decrease in the coming year, from ($4.12) to ($4.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avalo Therapeutics is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avalo Therapeutics is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Avalo Therapeutics (NASDAQ:AVTX) StockAvalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Read More AVTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVTX Stock News HeadlinesSeptember 27, 2023 | finance.yahoo.comBestGrowthStocks.com Issues a Comprehensive Analysis of Avalo TherapeuticsSeptember 26, 2023 | benzinga.comWhy Avalo Therapeutics Stock Is Up TodayOctober 4, 2023 | Legacy Research (Ad)Watch SHOCKING Footage of AI Facility with Ties to Elon MuskI recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.September 22, 2023 | benzinga.comWhat's Going On With Avalo Therapeutics (AVTX) Stock?September 18, 2023 | benzinga.comWhy Rubicon Technologies Shares Are Trading Lower By Over 7%; Here Are 20 Stocks Moving PremarketSeptember 13, 2023 | benzinga.comWhy Eiger BioPharmaceuticals Shares Are Trading Lower By 52%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionSeptember 13, 2023 | msn.comAvalo drops three rare disease assets amid ongoing challengesSeptember 13, 2023 | benzinga.comWhy Mainz Biomed Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving PremarketOctober 4, 2023 | Behind the Markets (Ad)"Chilling War Games Show US Forces Crushed" – FOX NEWS=== BREAKING === "Chilling War Games Show US Forces Crushed" - FOX NEWS After losing to China in repeated war games, U.S. military to spend billions on new "living missile" for armed forces. Investors stand to reap 35,960% on shares of small defense contractor that makes powerful new weapon. Get the name of the stock here >>>September 12, 2023 | marketwatch.comAvalo Therapeutics Shares Rise 53% After Deal to Divest Certain AssetsSeptember 12, 2023 | msn.comWhy Microcap Biotech Firm Avalo Therapeutics Stock Is Trading Higher Today?September 12, 2023 | markets.businessinsider.comCrude Oil Rises 2%; Avalo Therapeutics Shares Spike HigherSeptember 12, 2023 | markets.businessinsider.comAvalo Therapeutics To Sell 800 Series Programs To AUG Therapeutics; Stock SurgesSeptember 12, 2023 | seekingalpha.comAvalo enters agreement to divest AVTX-800 seriesSeptember 12, 2023 | finance.yahoo.comAvalo Enters into Agreement to Divest AVTX-800 SeriesSeptember 6, 2023 | finance.yahoo.comAvalo to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 22, 2023 | finance.yahoo.comIs Avalo Therapeutics (AVTX) A Hidden Gem or A Value Trap?August 3, 2023 | msn.comAvalo Therapeutics, Inc. (AVTX) Reports Q2 Loss, Misses Revenue EstimatesAugust 3, 2023 | finance.yahoo.comAvalo Reports Second Quarter 2023 Financial Results and Provides Business UpdatesJuly 26, 2023 | benzinga.comAvalo Therapeutics Stock (NASDAQ:AVTX) Insider TradesJuly 6, 2023 | finance.yahoo.comAvalo to Participate in SVB Securities Therapeutics ForumJune 28, 2023 | benzinga.comAvalo Therapeutics 10% Owner Sold $1.03M In Company StockJune 27, 2023 | msn.comAvalo (AVTX) Fails to Meet Goal in Asthma Study, Stock Down 89%June 26, 2023 | msn.comU.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.04%June 26, 2023 | msn.comWhy Are Avalo Therapeutics Shares Plummeting On MondayJune 26, 2023 | msn.comAvalo Plummets 80% on Phase 2 Disappointment in AsthmaJune 26, 2023 | marketwatch.comAvalo Therapeutics Shares Hit 52-Week Low After Trial Misses Primary EndpointSee More Headlines Receive AVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avalo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AVTX Company Calendar Last Earnings8/03/2023Today10/04/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AVTX CUSIPN/A CIK1534120 Webwww.avalotx.com Phone(410) 522-8707FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.00 High Stock Price Forecast$10.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+7,042.9%Consensus RatingReduce Rating Score (0-4)1.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,660,000.00 Net Margins-146.01% Pretax Margin-145.84% Return on EquityN/A Return on Assets-75.99% Debt Debt-to-Equity RatioN/A Current Ratio0.33 Quick Ratio0.33 Sales & Book Value Annual Sales$18.05 million Price / Sales0.16 Cash FlowN/A Price / Cash FlowN/A Book Value($1.16) per share Price / Book-0.12Miscellaneous Outstanding Shares20,250,000Free Float11,056,000Market Cap$2.84 million OptionableOptionable Beta1.21 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Garry A. Neil M.D. (Age 69)Chairman, Pres & CEO Comp: $601.9kMr. Christopher Ryan Sullivan (Age 39)CFO & Head of Investor relations Comp: $466.94kDr. Solomon H. Snyder M.D. (Age 84)Founder and Chairman of Scientific Advisory Board Dr. Barbara S. Slusher Ph.D. (Age 58)Founder and Member of Scientific Advisory Board Dr. Lisa Hegg Ph.D.Sr. VP of Program Management, Corp. Infrastructure & Clinical OperationsMs. Colleen MatkowskiSr. VP of Global Regulatory Affairs & Quality AssuranceDr. Dino C. Miano Ph.D.Sr. VP of CMC & Technical OperationsMore ExecutivesKey CompetitorsAmpio PharmaceuticalsNYSE:AMPEAditxtNASDAQ:ADTXBellicum PharmaceuticalsNASDAQ:BLCM180 Life SciencesNASDAQ:ATNFDermata TherapeuticsNASDAQ:DRMAView All CompetitorsInsiders & InstitutionsVR Adviser LLCBought 250,000 shares on 8/11/2023Ownership: 6.173%Armistice Capital, LlcSold 2,746,138 sharesTotal: $1.68 M ($0.61/share)Caissa Capital Management Ltd.Bought 2,000 shares on 6/20/2023Total: $8,280.00 ($4.14/share)Caissa Capital Management Ltd.Bought 3,000 shares on 6/16/2023Total: $11,700.00 ($3.90/share)Caissa Capital Management Ltd.Bought 6,000 shares on 6/14/2023Total: $20,880.00 ($3.48/share)View All Insider TransactionsView All Institutional Transactions AVTX Stock - Frequently Asked Questions Should I buy or sell Avalo Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avalo Therapeutics in the last year. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" AVTX shares. View AVTX analyst ratings or view top-rated stocks. What is Avalo Therapeutics' stock price forecast for 2023? 3 equities research analysts have issued 12 month price targets for Avalo Therapeutics' shares. Their AVTX share price forecasts range from $10.00 to $10.00. On average, they expect the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 7,042.9% from the stock's current price. View analysts price targets for AVTX or view top-rated stocks among Wall Street analysts. How have AVTX shares performed in 2023? Avalo Therapeutics' stock was trading at $5.0401 at the beginning of 2023. Since then, AVTX stock has decreased by 97.2% and is now trading at $0.14. View the best growth stocks for 2023 here. Are investors shorting Avalo Therapeutics? Avalo Therapeutics saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 3,070,000 shares, an increase of 220.1% from the August 31st total of 959,000 shares. Based on an average trading volume of 45,360,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 15.8% of the company's shares are short sold. View Avalo Therapeutics' Short Interest. When is Avalo Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our AVTX earnings forecast. How were Avalo Therapeutics' earnings last quarter? Avalo Therapeutics, Inc. (NASDAQ:AVTX) issued its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.31. The business earned $0.64 million during the quarter, compared to analysts' expectations of $1 million. When did Avalo Therapeutics' stock split? Avalo Therapeutics's stock reverse split on Friday, July 8th 2022. The 1-12 reverse split was announced on Friday, July 8th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 8th 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What is Avalo Therapeutics' stock symbol? Avalo Therapeutics trades on the NASDAQ under the ticker symbol "AVTX." How do I buy shares of Avalo Therapeutics? Shares of AVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Avalo Therapeutics' stock price today? One share of AVTX stock can currently be purchased for approximately $0.14. How much money does Avalo Therapeutics make? Avalo Therapeutics (NASDAQ:AVTX) has a market capitalization of $2.84 million and generates $18.05 million in revenue each year. The company earns $-41,660,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis. How can I contact Avalo Therapeutics? Avalo Therapeutics' mailing address is 540 Gaither Rd Ste 400, Rockville, Maryland 20850-6713. The official website for the company is www.avalotx.com. The company can be reached via phone at (410) 522-8707 or via email at ir@cerecor.com. This page (NASDAQ:AVTX) was last updated on 10/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.